

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. _____)*

Voyager Therapeutics, Inc. (Name of Issuer)
Common Stock

(Title of Class of Securities)

92915B106 (CUSIP Number)

November 11, 2015

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

? Rule 13d-1(b)

? Rule 13d-1(c)

? Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior
cover page.

The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of
the Securities Exchange Act of 1934 ("Act") or otherwise subject
to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act (however, see the Notes).

CUSIP No. 92915B106

13G

Page 2 of 6 Pages

1.

NAMES OF REPORTING PERSONS

Brookside Capital Partners Fund, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a) ?

(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,176,471

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,176,471

8.

SHARED DISPOSITIVE POWER

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,176,471

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.52%

12.

TYPE OF REPORTING PERSON (see instructions)

PN

CUSIP No. 92915B106

13G

Page 3 of 6 Pages

1.

NAMES OF REPORTING PERSONS

Brookside Capital Trading Fund, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) ?

(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

350,000

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

350,000

8.

SHARED DISPOSITIVE POWER

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

350,000

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.34%

12.

TYPE OF REPORTING PERSON (see instructions)

PN

CUSIP No. 92915B106

13G

Page 4 of 6 Pages

Item 1.

(a)

Name of Issuer

The name of the issuer to which this filing on Schedule 13G
relates is Voyager Therapeutics, Inc. (the "Company")

(b)

Address of Issuer's Principal Executive Offices
The principal executive offices of the Company are located
at 75 Sidney Street, Cambridge, MA 02139.

Item 2.

(a)

Name of Person Filing

This Statement is being filed on behalf the following (collectively,
the "Reporting Persons"): (1) Brookside Capital
Partners Fund, L.P., a Delaware limited partnership ("Partners Fund")
, whose sole general partner is Brookside Capital
Investors, L.P., a Delaware limited partnership ("Brookside Investors")
, whose sole general partner is Brookside
Capital Management, LLC, a Delaware limited liability company
("Brookside Management"); and (2) Brookside
Capital Trading Fund, L.P., a Delaware limited partnership ("Trading Fund")
, whose sole general partner is Brookside
Capital Investors II, L.P., a Delaware limited partnership
("Brookside Investors II"), whose sole general partner is
Brookside Management.

The Reporting Persons have entered into a Joint Filing Agreement, dated
November 18, 2015, a copy of which is filed
with this Schedule 13G as Exhibit A, pursuant to which the Reporting
Persons have agreed to file this statement jointly
in accordance with the provisions of Rule 13d-1(k) (1) under the
Securities Exchange Act of 1934.

(b)

Address of the Principal Office or, if none, residence
The principal business address of each of the Partners Fund, the
Trading Fund, Brookside Investors, Brookside
Investors II and Brookside Management is c/o Brookside Capital, LLC,
John Hancock Tower, 200 Clarendon Street,
Boston, MA 02116.

(c)

Citizenship

Each of the Partners Fund, Trading Fund, Brookside Investors, Brookside
Investors II and Brookside Management is
organized under the laws of the State of Delaware.

(d)

Title of Class of Securities

The class of equity securities of the Company to which this filing on
Schedule 13G relates is Common Stock
("Common Stock").

(e)

CUSIP Number

The CUSIP number of the Company's Common Stock is 92915B106.

Item 3. If this statement is filed pursuant to 240.13d-1(b) or

240.13d-2(b) or (c), check whether the person filing is a:

(a)

?

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

?

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

?

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

?

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)

?

An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);

(f)

?

An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

(g)

?

A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

(h)

?

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

?

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

?

Group, in accordance with 240.13d-1(b)(1)(ii)(J).

[x] If this statement is filed pursuant to 240.13d-1(c), check this box.
Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned: 1,526,471

(b)

Percent of class: 5.86% based upon 26,034,710 shares of Common Stock outstanding.

(c)

Number of shares as to which the person has: 1,526,471.

(i)

Sole power to vote or to direct the vote: 1,526,471.

(ii)

Shared power to vote or to direct the vote: 0.

(iii)

Sole power to dispose or to direct the disposition of: 1,526,471.

(iv)

Shared power to dispose or to direct the disposition of: 0.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent

Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 92915B106

13G

Page 6 of 6 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 18, 2015

BROOKSIDE CAPITAL PARTNERS FUND, L.P.

By: Brookside Capital Investors, L.P.,
its general partner

By: Brookside Capital Management, LLC,
its general partner

By:

Name: William E. Pappendick IV
Title: Managing Director

BROOKSIDE CAPITAL TRADING FUND, L.P.

By: Brookside Capital Investors II, L.P.,
its general partner

By: Brookside Capital Management, LLC,
its general partner

Name: William E. Pappendick IV
Title: Managing Director

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF
SCHEDULE 13G

The undersigned hereby agree as follows:

(i) The Statement on Schedule 13G, and any amendments thereto, to which this Agreement is annexed as Exhibit A is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: November 18, 2015

BROOKSIDE CAPITAL PARTNERS FUND, L.P.

By: Brookside Capital Investors, L.P.,
its general partner

By: Brookside Capital Management, LLC,
its general partner

By:
Name: William E. Pappendick IV
Title: Managing Director

BROOKSIDE CAPITAL TRADING FUND, L.P.

By: Brookside Capital Investors II, L.P.,
its general partner
By: Brookside Capital Management, LLC,
its general partner

By:
Name: William E. Pappendick IV
Title: Managing Director

The percentage of Common Stock reported owned by the Reporting Persons
is based upon 26,034,710 shares of Common Stock
outstanding as reported in the Issuer's Prospectus dated November 12, 2015.

The percentage of Common Stock reported owned by the Reporting Persons
is based upon 26,034,710 shares of Common Stock
outstanding as reported in the Issuer's Prospectus dated November 12, 2015.

48220740_1
48220740_1
48220740_1